VESSL Therapeutics

VESSL Therapeutics Overview

VESSL Therapeutics develops cell-based therapies for patients who suffer from cardiovascular and other vascular-related conditions and cannot be treated adequately with existing therapeutic modalities. Its core technology is based on an integrative approach for the treatment of cardiovascular disease. VESSLs two leading products, MultiGeneAngio and MultiGeneGraft, have been approved by the FDA for clinical studies, and two phase 1/2 clinical trials with MultiGeneAngio have been completed. MultiGeneAngio is a combination of two cell types and two genes, and MultiGeneGraft is the combination of cells, genes, and a synthetic graft. These two technologies are used in therapies for patients with peripheral artery disease and coronary artery disease, and for patients with renal disease requiring hemodialysis. The companys products are based on the patients own cells, isolated from a short vein segment taken from the patients arm under local anesthesia. The isolated cells are activated by the insertion of specific genes and then reintroduced to the patient. The FDA has granted an Investigational New Drug (IND) authorization for MultiGeneGraft.

Cumulative Funding Raised Over Time ($)

Latest News

Oct 29, 2021 · www.globes.co.il

growth-positive

החברה שחתמה עם טבע - ואז התרסקה - חוזרת לסיבוב נוסף

Vessl, formerly known as MGVS, is a medical technology company that has developed a treatment for vascular occlusion. The company genetically engineers cells from a patients vein to promote the growth of new blood vessels. Vessl has also developed a synthetic organ composed of a synthetic material and genetically engineered cells. The company was founded by Moshe Flugelman and Binyamin Zeevi and has raised $16 million in funding from investors including Tamir Fishman, XT Ventures, Aviv Venture Capital, and RunYoung. The company is based in Yokneam, Israel.

InvestmentExpand

Apr 25, 2021 · en.globes.co.il

growth-positive

Israeli co Vessl Therapeutics raises $16m

Israeli cell-based therapy developer Vessl Therapeutics has completed a $16 million financing round led by Chinas RunYoung Capital. Vessls core technology enables the company to develop treatments for a wide range of blood-vessel-related disorders. The financing round brings the total amount raised by Vessl to $20 million. The company aims to create groundbreaking therapies for patients with various diseases for whom conventional treatments have failed or are unsuitable.

Investment

Jan 26, 2012 · www.globes.co.il

growth-positive

Teva raises investment in cell therapy co

Teva Pharmaceutical Industries Ltd. has exercised its option to make an additional investment in MultiGene Vascular Systems Ltd. at a company value of $135 million. The investment follows the completion of a clinical trial for MultiGene Vascular Systems treatment of chronic critical limb ischemia. Teva had previously invested $4 million in MultiGene Vascular Systems in 2009. The investors in MultiGene Vascular Systems include Teva, Aviv Venture Capital, DFJ Tamir Fishman Ventures Ltd., and Ofer Hi Tech Ltd.

Investment

Funding

Team Members

3

Employees: 1-10

Web & Social Links

Locations

HaYozma Street 6, Yokne'am Illit, Israel

Photos & Videos

2 item(s)

VESSL Therapeutics Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info